Form 4 for RNTX Rein Therapeutics, Inc.
Accepted 2026-05-28 20:15:59 ET · period of report 2026-05-21 · accession 0001193125-26-245832 · SEC index · Original document
Summary rows
Aggregated the way they appear in lists: one row per insider, transaction code and security table.
| X | Filed | Traded | Ticker | Insider | Title | Type | Price | Qty | Owned | ΔOwn | Value |
|---|---|---|---|---|---|---|---|---|---|---|---|
| M | 2026-05-28 20:15 | 2026-05-21+ | RNTX | VON RICKENBACH JOSEF H | Dir | P - Purchase | $1.05 | +47.1K | 62.5K | +305% | +$49.6K |
Purchase Sale Sale after option exercise All abbreviations
Every reported transaction
| # | Table | Security | Date | Code | A/D | Shares | Price | Owned after | Own | Exercise / expiry | Underlying | Footnotes |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 1 | Common | Common stock , $0.001 par value | 2026-05-21 | P | A | 3,420 | $1.04 | 18,874 | D | — | — | (F1) The reported shares were purchased in the open market in multiple transactions at prices ranging from $1.05 and $1.035 on May 21, 2026, $1.07 and $1.01 on May 22, 2026, $1.07 and $1.03 on May 26, 2026 and $1.08 and $1.03 on May 27, 2026. The prices reported in Column 4 are a weighted average price for purchase on the respective day. The reporting person undertakes to provide to Rein Therapeutics, Inc., any stockholder of Rein Therapeutics, Inc. or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares purchased at each separate price within the ranges set forth in this footnote (1). (F1) The reported shares were purchased in the open market in multiple transactions at prices ranging from $1.05 and $1.035 on May 21, 2026, $1.07 and $1.01 on May 22, 2026, $1.07 and $1.03 on May 26, 2026 and $1.08 and $1.03 on May 27, 2026. The prices reported in Column 4 are a weighted average price for purchase on the respective day. The reporting person undertakes to provide to Rein Therapeutics, Inc., any stockholder of Rein Therapeutics, Inc. or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares purchased at each separate price within the ranges set forth in this footnote (1). |
| 2 | Common | Common stock , $0.001 par value | 2026-05-22 | P | A | 15,950 | $1.05 | 34,824 | D | — | — | (F1) The reported shares were purchased in the open market in multiple transactions at prices ranging from $1.05 and $1.035 on May 21, 2026, $1.07 and $1.01 on May 22, 2026, $1.07 and $1.03 on May 26, 2026 and $1.08 and $1.03 on May 27, 2026. The prices reported in Column 4 are a weighted average price for purchase on the respective day. The reporting person undertakes to provide to Rein Therapeutics, Inc., any stockholder of Rein Therapeutics, Inc. or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares purchased at each separate price within the ranges set forth in this footnote (1). (F1) The reported shares were purchased in the open market in multiple transactions at prices ranging from $1.05 and $1.035 on May 21, 2026, $1.07 and $1.01 on May 22, 2026, $1.07 and $1.03 on May 26, 2026 and $1.08 and $1.03 on May 27, 2026. The prices reported in Column 4 are a weighted average price for purchase on the respective day. The reporting person undertakes to provide to Rein Therapeutics, Inc., any stockholder of Rein Therapeutics, Inc. or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares purchased at each separate price within the ranges set forth in this footnote (1). |
| 3 | Common | Common stock , $0.001 par value | 2026-05-26 | P | A | 23,190 | $1.06 | 58,014 | D | — | — | (F1) The reported shares were purchased in the open market in multiple transactions at prices ranging from $1.05 and $1.035 on May 21, 2026, $1.07 and $1.01 on May 22, 2026, $1.07 and $1.03 on May 26, 2026 and $1.08 and $1.03 on May 27, 2026. The prices reported in Column 4 are a weighted average price for purchase on the respective day. The reporting person undertakes to provide to Rein Therapeutics, Inc., any stockholder of Rein Therapeutics, Inc. or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares purchased at each separate price within the ranges set forth in this footnote (1). (F1) The reported shares were purchased in the open market in multiple transactions at prices ranging from $1.05 and $1.035 on May 21, 2026, $1.07 and $1.01 on May 22, 2026, $1.07 and $1.03 on May 26, 2026 and $1.08 and $1.03 on May 27, 2026. The prices reported in Column 4 are a weighted average price for purchase on the respective day. The reporting person undertakes to provide to Rein Therapeutics, Inc., any stockholder of Rein Therapeutics, Inc. or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares purchased at each separate price within the ranges set forth in this footnote (1). |
| 4 | Common | Common stock , $0.001 par value | 2026-05-27 | P | A | 4,500 | $1.07 | 62,514 | D | — | — | (F1) The reported shares were purchased in the open market in multiple transactions at prices ranging from $1.05 and $1.035 on May 21, 2026, $1.07 and $1.01 on May 22, 2026, $1.07 and $1.03 on May 26, 2026 and $1.08 and $1.03 on May 27, 2026. The prices reported in Column 4 are a weighted average price for purchase on the respective day. The reporting person undertakes to provide to Rein Therapeutics, Inc., any stockholder of Rein Therapeutics, Inc. or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares purchased at each separate price within the ranges set forth in this footnote (1). (F1) The reported shares were purchased in the open market in multiple transactions at prices ranging from $1.05 and $1.035 on May 21, 2026, $1.07 and $1.01 on May 22, 2026, $1.07 and $1.03 on May 26, 2026 and $1.08 and $1.03 on May 27, 2026. The prices reported in Column 4 are a weighted average price for purchase on the respective day. The reporting person undertakes to provide to Rein Therapeutics, Inc., any stockholder of Rein Therapeutics, Inc. or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares purchased at each separate price within the ranges set forth in this footnote (1). |